retroviral MGMT-transduced hematopoietic cells (Case Western)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameretroviral MGMT-transduced hematopoietic cells (Case Western)
Drug Alias NameAutologous MFG-G156A MGMT-transduced CD34+ therapymethyltransferase-transduced autologous cell therapy (Case Western)G156A MGMT+
ClassificationBiologics
Mechanisms of ActionHaematopoiesis stimulants
TargetsUpdating
Therapy Area/IndicationsLeukopeniaAnemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCase Western Reserve University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCase Western Reserve University
Active IndicationsN/A
Inactive IndicationsLeukopeniaAnemia

Other Information

ATC CodeN/A
Related LinksN/A